HALO X-ray Technologies (HXT), a spin-out company from Nottingham Trent University (NTU) and Cranfield University has relocated to MediCity, the innovation hub on the Boots site in Beeston, Nottingham. The HXT team are pioneering the development of next-generation X-ray technologies to improve significantly the speed, accuracy and cost-efficiency of the detection process. Expansion plans have required the company to take a 900 square foot MediCity office in readiness for the recruitment of at least three new members of staff in early 2016.

Formerly based on the Nottingham Trent University Clifton Campus, HXT was launched in 2012 to commercialise a large programme of research led by Professor Paul Evans, Head of The Imaging Science Group at NTU and Professor Keith Rogers, Director of the Cranfield Forensic Institute. The specially-equipped facility on the Clifton Campus, combined with funding from a variety of sources, has enabled the necessary prototype testing to prove the capability of the technology. The applications for this new technology include aviation and border security, the medical sector and in the control of industrial process.

Dr. Simon Godber, HXT Director and Chief Executive Officer is heading-up the expansion into MediCity and is especially keen to draw on the incubator’s global connections in the medical device and healthcare sectors.

“MediCity is an ideal base for the next stage of our development. We have benefitted greatly from the excellent research facilities at Nottingham Trent University as well as their invaluable advice and financial support in the pre-start-up and early commercial phases. Now we are ready to fly-the-nest and experience the risks and rewards of growing this venture. Given the close working relationship between MediCity and NTU, we hope to benefit from both organisations’ expertise.”

MediCity is a collaboration between Boots, the UK’s leading health and beauty retailer, and BioCity, the UK’s leading life sciences incubation business. Businesses like HXT benefit from BioCity’s experience of growing successful businesses in specialised incubator environments and from Boots expertise in the global healthcare market.

HXT’s expansion has created job opportunities which Dr Godber is keen to fill. These cover software and systems engineering as well as office support.

David Browning, Managing Director of MediCity, will be working closely with HXT to ensure a smooth transition onto the site and to assist the next phase of business development: “HALO X-ray Technologies is a truly ground-breaking company and it is a privilege to have them join the MediCity community of entrepreneurs. Their energy and enthusiasm for what they do, and what they want to achieve, comes from their many years in industry and the technical support of two of the UK’s leading research Universities. I know they will contribute to helping our other companies flourish as they too grow.”

ENDS

Media contact; Louise Third, Director, Integra Communications: 0115 784 0081 / 07773 288342 or click here to email.

Latest Opportunities

Study brief: The effects of a recovery gel on endurance cycling performance in the heat

The popularity of endurance sports like cycling and running has grown significantly over the past…

UKRI unveils new £9 million proof-of-concept fund

The UKRI Proof of Concept funding opportunity aims to support and accelerate the development of…

Peer advice on “demand forecasting strategies”

An established Midlands-based health manufacturer is keen to hear from others about their demand forecasting…

Latest News

Digital mental health technologies guidance launched to help manufacturers and safeguard users

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued new guidance to help manufacturers…

Scientific Laboratory Supplies' service arm acquires new company

The dedicated service arm of Scientific Laboratory Supplies Group (SLS), C&M Scientific, has announced the…

Golden Ticket Programme 2025 crowns winner

Melio Bio, a biotech dedicated to the discovery and development of novel inhibitors targeting a…